Thromboembolic Complications in Severe COVID-19: Current Antithrombotic Strategies and Future Perspectives.

Q2 Medicine

Cardiovascular and Hematological Disorders - Drug Targets Pub Date : 2021-01-01 DOI:10.2174/1871529X21666210315123347

Juan J Rodriguez, Oscar C Munoz, Mateo Porres-Aguilar, Debabrata Mukherjee

引用次数: 6

Abstract

The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS- CoV-2) is our latest pandemic and has turned out to be a global public health crisis. One of the special characteristics of this disease is that it may predispose patients to thrombotic disease both in the venous and arterial circulation. We review arterial and venous thromboembolic complications in patients with COVID-19, epidemiology, pathogenesis, hematologic biomarkers, and current antithrombotic strategies. Future perspectives and clinical trials are ongoing to determine the best thromboprophylaxis strategies in the hospitalized patients with severe COVID-19.

查看原文本刊更多论文

重症COVID-19的血栓栓塞并发症:当前抗血栓策略和未来展望

由严重急性呼吸系统综合征冠状病毒(SARS- CoV-2)引起的冠状病毒病2019 (COVID-19)是我们最新的大流行，已成为全球公共卫生危机。这种疾病的一个特殊特征是，它可能使患者易患静脉和动脉循环中的血栓性疾病。我们回顾了COVID-19患者的动脉和静脉血栓栓塞并发症、流行病学、发病机制、血液学生物标志物和当前的抗血栓策略。未来的观点和临床试验正在进行中，以确定重症COVID-19住院患者的最佳血栓预防策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular and Hematological Disorders - Drug Targets Medicine-Cardiology and Cardiovascular Medicine

CiteScore

1.90

自引率

0.00%

发文量

期刊介绍： Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow.